The stem cell niche as a pharmaceutical target for prevention of skeletal metastases

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Advanced cancers of the prostate and breast commonly progress by metastasizing to the skeleton, where they are incurable but cause serious morbidity and contribute to mortality. Growth of tumor in bone takes several years, opening a large window for pharmaceutical prevention of metastatic progression. Bone provides a unique microenvironment for tumor growth, including niches occupied by hematopoietic and mesenchymal stem cells. Recent data suggest that circulating tumor cells usurp these niches and compete with the normal stem cell occupants. Agents that encourage normal hematopoiesis or bone formation could inhibit colonization of bone by tumor stem cells and prevent or delay metastatic progression. It may be possible to develop high-throughput assays to test compounds for their ability to suppress tumor stem cell occupation of skeletal niches, thus decreasing metastatic progression in at-risk patients.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume12
Issue number3
StatePublished - Mar 2012

Fingerprint

Stem Cell Niche
Neoplastic Stem Cells
Neoplasm Metastasis
Bone and Bones
Pharmaceutical Preparations
Circulating Neoplastic Cells
Tumor Microenvironment
Hematopoiesis
Growth
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Occupations
Osteogenesis
Skeleton
Prostatic Neoplasms
Stem Cells
Breast Neoplasms
Morbidity
Mortality
Neoplasms

Keywords

  • Anti-resorptive agents
  • Bone metastases
  • Bone-anabolic agents
  • Breast cancer
  • Endosteal niche
  • Hematopoietic niche
  • Mesenchymal cell niche
  • Prostate cancer
  • Stem cell niche

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

The stem cell niche as a pharmaceutical target for prevention of skeletal metastases. / Chirgwin, John.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 12, No. 3, 03.2012, p. 187-193.

Research output: Contribution to journalArticle

@article{9a92b6337c864aa9b24d3640adca9b18,
title = "The stem cell niche as a pharmaceutical target for prevention of skeletal metastases",
abstract = "Advanced cancers of the prostate and breast commonly progress by metastasizing to the skeleton, where they are incurable but cause serious morbidity and contribute to mortality. Growth of tumor in bone takes several years, opening a large window for pharmaceutical prevention of metastatic progression. Bone provides a unique microenvironment for tumor growth, including niches occupied by hematopoietic and mesenchymal stem cells. Recent data suggest that circulating tumor cells usurp these niches and compete with the normal stem cell occupants. Agents that encourage normal hematopoiesis or bone formation could inhibit colonization of bone by tumor stem cells and prevent or delay metastatic progression. It may be possible to develop high-throughput assays to test compounds for their ability to suppress tumor stem cell occupation of skeletal niches, thus decreasing metastatic progression in at-risk patients.",
keywords = "Anti-resorptive agents, Bone metastases, Bone-anabolic agents, Breast cancer, Endosteal niche, Hematopoietic niche, Mesenchymal cell niche, Prostate cancer, Stem cell niche",
author = "John Chirgwin",
year = "2012",
month = "3",
language = "English",
volume = "12",
pages = "187--193",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - The stem cell niche as a pharmaceutical target for prevention of skeletal metastases

AU - Chirgwin, John

PY - 2012/3

Y1 - 2012/3

N2 - Advanced cancers of the prostate and breast commonly progress by metastasizing to the skeleton, where they are incurable but cause serious morbidity and contribute to mortality. Growth of tumor in bone takes several years, opening a large window for pharmaceutical prevention of metastatic progression. Bone provides a unique microenvironment for tumor growth, including niches occupied by hematopoietic and mesenchymal stem cells. Recent data suggest that circulating tumor cells usurp these niches and compete with the normal stem cell occupants. Agents that encourage normal hematopoiesis or bone formation could inhibit colonization of bone by tumor stem cells and prevent or delay metastatic progression. It may be possible to develop high-throughput assays to test compounds for their ability to suppress tumor stem cell occupation of skeletal niches, thus decreasing metastatic progression in at-risk patients.

AB - Advanced cancers of the prostate and breast commonly progress by metastasizing to the skeleton, where they are incurable but cause serious morbidity and contribute to mortality. Growth of tumor in bone takes several years, opening a large window for pharmaceutical prevention of metastatic progression. Bone provides a unique microenvironment for tumor growth, including niches occupied by hematopoietic and mesenchymal stem cells. Recent data suggest that circulating tumor cells usurp these niches and compete with the normal stem cell occupants. Agents that encourage normal hematopoiesis or bone formation could inhibit colonization of bone by tumor stem cells and prevent or delay metastatic progression. It may be possible to develop high-throughput assays to test compounds for their ability to suppress tumor stem cell occupation of skeletal niches, thus decreasing metastatic progression in at-risk patients.

KW - Anti-resorptive agents

KW - Bone metastases

KW - Bone-anabolic agents

KW - Breast cancer

KW - Endosteal niche

KW - Hematopoietic niche

KW - Mesenchymal cell niche

KW - Prostate cancer

KW - Stem cell niche

UR - http://www.scopus.com/inward/record.url?scp=84857748339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857748339&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 187

EP - 193

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 3

ER -